Genes functioning in epidermal growth factor receptor (EGFR) signaling pathways are among the most frequently activated oncogenes in human cancers. We have conducted a comparative analysis of functional footprints (that is, effect on signaling and transcriptional landscapes in cells) associated with oncogenic and tumor suppressor mutations in EGFR pathway genes in human cancers. We have found that mutations in the EGFR pathway differentially have an impact on signaling and metabolic pathways in cancer cells in a mutation-and tissue-selective manner. For example, although signaling and metabolic profiles of breast tumors with PIK3CA or AKT1 mutations are, as expected, highly similar, they display markedly different, sometimes even opposite, profiles to those with ERBB2 or EGFR amplifications. On the other hand, although low-grade gliomas and glioblastomas, both brain cancers, driven by EGFR amplifications are highly functionally similar, their functional footprints are significantly different from lung and breast tumors driven by EGFR or ERBB2. Overall, these observations argue that, contrary to expectations, the mechanisms of tumorigenicity associated with mutations in different genes along the same pathway, or in the same gene across different tissues, may be highly different. We present evidence that oncogenic functional footprints in cancer cell lines have significantly diverged from those in tumor tissues, which potentially explains the discrepancy of our findings with the current knowledge. Nevertheless, our analyses reveal a common inflammatory response signature in EGFR-driven human cancers of different tissue origins. Our results may have implications in the design of therapeutic strategies in cancers driven by these oncogenes.
INTRODUCTION
Receptor tyrosine kinases of the epidermal growth factor receptor (EGFR) family, such as EGFR and ERBB2, are frequently activated in human cancers. Upon stimulation by its ligands, these receptor tyrosine kinases activate a number of downstream signaling pathways that promote proliferation, growth and survival in cells. 1, 2 Some of the most notable of such pathways include the Ras/mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase/Akt signaling pathways, whose role in promoting growth, survival and tumor progression have been well characterized. 3 Accordingly, activating mutations in the Ras/ MAPK pathway, that is, in NRAS, KRAS and BRAF oncogenes, are very common in melanomas and in lung and colon cancers, whereas mutations in PIK3CA and AKT1 genes are frequently observed in breast cancers. Similarly, inactivating mutations in NF1 and phosphatase and tensin homolog (PTEN) genes, inhibitors of Ras and PI-3K/Akt signaling, respectively, are also frequently observed in different cancers.
Most of the current targeted therapy strategies in cancers driven by mutations in the EGFR pathway genes focus on targeting of the driver oncogene, such as targeting EGFR with gefitinib or erlotinib in EGFR-mutated lung cancers 4 or targeting BRAF with vemurafenib in BRAF-mutant melanomas. 5 In addition, there is an effort on developing inhibitors to target some of the common downstream nodes along the EGFR pathway, such as Akt, MAPK or mammalian target of rapamycin (mTOR) in cancers with activating mutations in the EGFR pathway. 3 However, the proto-oncogenes of the EGFR pathway have multiple roles in the cell that are independent of their 'most famous' targets. For example, EGFR has almost 300 direct interacting partners listed in public protein-protein interaction databases (not shown). Similarly, Ras is known to have multiple signaling targets independent of its most studied downstream targets, Raf and Akt, 6 and the Raf kinase has multiple functions that are independent of its most studied downstream target MEK. 7 Therefore, it is possible that these oncogenes engage different mechanisms in promoting tumorigenesis, which may have significant implications in the design of therapeutic strategies against cancers driven by these oncogenes.
Here, by using the genome-wide data on mRNA and protein expressions, as well as somatic mutations and genomic copy numbers for different human cancers collected by The Cancer Genome Atlas (TCGA; https://tcga-data.nci.nih.gov/tcga/), we have conducted a comparative analysis of functional footprints of the oncogenes and tumor suppressors of the EGFR pathway. We define a functional footprint of an oncogene as the landscape of functional changes, at multiple levels of organization, directly or indirectly induced by the oncogenic mutation in the tumor. Our analyses reveal similarities and differences in functional footprints among gene mutations within and across tissue types. However, most notably, despite some expected similarities in downstream pathway activations, such as activation of the MAPK pathway by KRAS mutations, or of the Akt pathway by PIK3CA or PTEN mutations, we find that the functional footprints often show significant tissue selectivity. To explore tissue selectivity of functional footprints of an oncogene, we present a detailed analysis of EGFR and ERBB2 activations in breast, glioblastoma (GBM), lower-grade glioma (LGG) and lung tumor samples. However, despite the extensive differences in global functional profiles, we find that tumors driven by the EGFR oncogene often display an inflammatory response signature characterized by interferon, interleukin or Toll-like receptor (TLR) signaling, depending on the tissue type. This study, to our knowledge, is the first comprehensive analysis of global pathway profiles associated with EGFR pathway-driven human cancers.
RESULTS

Heterogeneity of transcriptional footprints in EGFR pathway mutations
We chose to study the seven oncogenes (EGFR, ERBB2, NRAS, KRAS, BRAF, PIK3CA and AKT1) and two tumor suppressors (PTEN and NF1) implicated in the EGFR signaling network that are most frequently mutated in human cancers ( Figure 1a ). To gain insight into global molecular profiles of human cancers associated with these mutations, we set to identify functional footprints (transcriptional or signaling) of these mutations. We define the transcriptional footprint of a mutation as the vector of individual impact scores (t-values) of the mutation on the expression of each gene in the transcriptome based on a multiple linear regression (MLR) model (Figure 1b and see Materials and methods). Use of MLR in our case allows for scoring of causal impacts of mutations on the mRNA levels of a gene, as it is unlikely that the causal direction will go the other way around (that is, mRNA-mutation). In addition, MLR allows for isolation of individual effects of each mutation by accounting for indirect confounding effects of other mutations in patients.
In contrast to a transcriptional footprint, a signaling footprint is defined as the vector of individual impact scores of the mutation on each post-translational modification as measured by reverse-phase protein arrays (RPPAs) in the TCGA data sets. We chose to study the functional footprints of the EGFR pathway genes in breast carcinoma (BRCA), colon adenocarcinoma (COAD), GBM, LGG, lung adenocarcinoma (LUAD) and skin melanoma (SKCM) samples where these mutations are most frequently observed (see Supplementary Information for mutation frequencies). For analyses, we used the extensive collection of RNAseq, gene copy number, RPPA and somatic mutation data sets for these cancers in TCGA.
We obtained transcriptional footprints for each mutation in each cancer type. We asked whether oncogenic aberrations of the EGFR pathway members have similar footprints. To answer this question, we performed all pairwise correlations of each transcriptional footprint in every cancer type. For each pairwise correlation, we only included t-values that had absolute values of 42 in at least one of the pair (that is, Po0.05 for correlation significance, see Materials and methods). As expected, based on prior knowledge, some of the most similar footprints belong to genes whose products are proximally located on a linear pathway, such as PIK3CA and AKT1 in BRCA, or KRAS and BRAF in LUAD and COAD, or NRAS and BRAF in SKCM (Figures 1c and d) . In addition, weaker but still strong similarities were observed between pairs of other mutations (for example, NRAS-KRAS in COAD, and EGFR and NF1 in LGG) that are expected to impact similar downstream pathways. However, this correlation map also reveals some unexpected observations. First, transcriptional footprints of some gene mutations, such as ERBB2 or EGFR amplifications in BRCA or LUAD, show no similarity to footprints of genes that function downstream of these receptors, such as PIK3CA or KRAS (see Figure 1c ). For example, the footprints of ERBB2 amplification had no similarity to those of PIK3CA, AKT1, NF1 mutations, or even of EGFR amplifications, in BRCA (Figure 1c) . Similarly, EGFR amplification footprints in LUAD had minimal similarity to KRAS, BRAF, NF1 or even EGFR mutations, in LUAD (Figure 1c ), indicating that these mutations lead to different downstream events. Another surprising observation was a minimal correlation among transcriptional footprints across cancers based on tissue of origin, even in the case of the same oncogene (see Figure 1c) . Indeed, generally, there is only weak, if any, correlation in transcriptional footprints of EGFR, PIK3CA, KRAS, BRAF or NF1 gene mutations across the cancer types. A notable exception to this is the high similarity of transcriptional footprints of EGFR in GBM and LGG, which are both tumors of the brain (see Figure 1c ). These observations suggest that although there is an overall similarity in the transcriptional footprints of EGFR pathway mutations, there is a significant heterogeneity across tissue types for the same oncogene, and also within a tissue type for certain oncogenes.
Heterogeneity of signaling footprints of EGFR pathway mutations Next, we compared signaling footprints of EGFR pathway mutations based on RPPA measurements of certain phosphorylated signaling proteins known to be involved downstream of the EGFR pathway mutations (see Figure 2a) . We chose these signaling outputs due to their known roles in EGFR signaling and the quality of the readings in RPPA data sets as assessed by at least one strong expected correlation (for example, phospho-MAPK (pMAPK) correlation with KRAS mutation, phospho-EGFR correlation with EGFR mutation or amplification). An analysis of signaling footprints of EGFR pathway mutations also reveals expected similarities as well as unexpected differences ( Figure 2b ). As no RPPA data were available for LGG at the time of this analysis, it was excluded from this portion of our study.
Expected correlations. Most consistent correlations of signaling events included some of the expected observations of high levels of tyrosine-phosphorylated EGFR and ERBB2 in tumors that carry EGFR or ERBB2 amplifications or EGFR mutations, high phosphoAkt levels (both S473 and T308 sites) in tumors with PIK3CA, AKT1 or PTEN mutations, and high phospho-MEK and pMAPK levels in tumors with KRAS or NRAS mutations (Figure 2b ). KRAS mutations in LUAD lead to the activation of HER3, Src, Raf/Mek/MAPK and mTOR/S6 pathways, but not Akt. However, KRAS mutations in COAD only lead to the activation of Src and Mek/MAPK/RSK/S6 pathways.
PTEN loss in SKCM and COAD. Interestingly, PTEN mutations in SKCM or COAD did not reveal any correlation with Akt activation, despite loss of PTEN expression in both. In case of COAD, this may be attributed to a concomitant downregulation of Akt protein (see Figure 2b ), which also correlates with a downregulation of AKT2 and AKT3 mRNA expression (not shown), indicating a possible feedback regulation of Akt activity in PTEN-negative colon cancers through a transcriptional mechanism. PTEN loss in SKCM did, however, show a significant correlation with phosphorylation of PKCa, which can also be activated by phosphoinositide 3-kinase signaling and inhibited by PTEN. 8 Therefore, PTEN loss in melanomas may serve to activate protein kinase C (PKC) signaling, rather than the Akt pathway, which seems to be the major target of PTEN mutations in other cancers (see Figure 2b) . Interestingly, PTEN mutations/loss in SKCM also correlates with ERBB2/HER2 overexpression. Such a correlation of PTEN loss with ERBB2/HER2 overexpression has not been previously reported. As ERBB2 is not amplified in SKCM (not shown) and PTEN mutations/loss does not correlate with increased ERBB2 mRNA levels (not shown), overexpression of ERBB2/HER2 protein in melanomas with PTEN loss must be through a posttranscriptional mechanism.
Other correlations. Activation levels of Src, STAT3 (signal transducer and activator of transcription factor 3), A-or c-Raf, mTOR, RSK, S6, stress-activated MAPKs (p38 and JNK) and of PKC were more variable. For example, mTOR and RSK activity, as measured by phospho levels of their downstream targets 4-EBP1 and S6, was strongly associated with ERBB2 amplifications and PTEN mutations in BRCA, KRAS and BRAF mutations in COAD, KRAS mutations in LUAD, and relatively weakly with PTEN mutations in GBM and EGFR amplifications in BRCA. On the other hand, stress-activated MAPKs p38 and JNK were activated by AKT1 mutations in BRCA and KRAS mutations in LUAD, whereas PKCa and PKCd were activated by EGFR mutations in LUAD and by PTEN mutations in SKCM. STAT3 activation as measured by its Y705 phosphorylation was only observed in LUAD with EGFR mutations and, to a lesser extent, in those with KRAS mutations.
Unexpected correlations. In addition to expected results, the analysis of signaling footprints also revealed surprising observations. For example, NRAS mutation in COAD is not associated with higher levels of activated MEK/MAPK or Akt, although KRAS, BRAF and NF1 mutations in COAD are (Figures 2b and c) . In addition, although NRAS in SKCM is strongly associated with MEK/MAPK activity, BRAF in SKCM is only associated with higher phospho-MEK, but not MAPK (Figures 2b and c) . Interestingly, BRAF mutations correlate strongly with Akt T308 phosphorylation, a target of PDK1, in LUAD and SKCM, but not with S473. Akt activity has been found to correlate with T308, but not S473, phosphorylation in several contexts, 9, 10 indicating that BRAF mutations in LUAD and SKCM are also strongly associated with Akt activity. Yet another surprising observation is an almost complete lack of correlation of EGFR/ERBB2 amplification or mutation with Akt or MAPK activation in BRCA, GBM and LUAD, although a correlation exists between ERBB2 amplification and A-Raf/MEK pathway activation, and between Akt phosphorylation on T308 and EGFR amplification in BRCA (see Figure 2b) . These results suggest that However, accounting for double mutations with NF1 did reveal some surprising effects in COAD. Interestingly, NRAS:NF1 double mutations, but not either of them alone, are associated with a significant Akt phosphorylation at S473 (Figure 2d ), but not at T308 (not shown), whereas PTEN:NF1 double mutations, but neither alone, are significantly associated with pMAPK levels ( Figure 2d ). In fact, NF1 mutations alone have a negative impact on pMAPK in COAD ( Figure 2d ). These observations show that multiple mutations in the EGFR pathway can elicit combinatorial non-additive effects on the signaling pathways. Many of the observations above are in stark contrast to the wellaccepted notion of signaling impacts of these mutations. For example, the effect of NRAS/BRAF mutations on the MAPK pathway activity has been extensively reported in the literature, 5 and EGFR overexpression both in vitro and in vivo is known to strongly activate Akt, STAT and MAPK pathways. 2 However, it is important to note that most of our current understanding of the role of these proteins in signal transduction comes from in vitro studies on tissue culture cells. Our analyses are done on tumor tissues from human patients and, therefore, may be more representative of bona fide effects of these mutations on signaling pathways. Moreover, some past studies on human tumor samples have identified similar conflicting results, such as lack of correlation of MAPK activity with BRAF mutations in the melanocytic nevi 11 and lack of correlation of EGFR activity with downstream pathway activations. 12 Therefore, it is possible that negative feedback mechanisms frequently act to restrict oncogenic pathways in these tumors. Accordingly, lack of Akt activation in ERBB2-amplifying BRCA, despite high expression of Akt mRNA (not shown) and protein, may be attributable to high levels of PTEN (see Figure 2b) , which may constitute a negative feedback to inhibit Akt in these tumors. In addition, these mutations may act through alternative downstream pathways, such as in the case of PTEN mutations in SKCM, where they lead to the activation of PKC rather than the better-known target Akt (see above).
Heterogeneity of pathway footprints in breast cancer Transcriptional footprints of EGFR pathway genes in BRCA showed a significant level of heterogeneity between receptors (ERBB2 and EGFR) and PIK3CA and AKT1 mutations (see Figure 1c) . We asked whether a similar heterogeneity is also present at a pathway level. For this purpose, we defined a pathway footprint to be a vector of individual impact scores of a mutation on the expression of predefined molecular pathways. Pathway footprints are derived from transcriptional footprints by NetWalk, 13 a computational network analysis procedure previously characterized by us and implemented in the software suite NetWalker.
14 Briefly, NetWalk is a random-walk method that integrates gene-centric values (such as gene expression or t-value) with a network of a priori molecular interactions to derive interaction-centric values (edge flux (EF) values) based on combined assessment of gene values and their interconnectivity. The EF values are then used to derive a unique log-likelihood score for each pathway/process (process flux value, or PF value) as defined in the NCBI BioSystems database (see Materials and methods). The PF-values have a high correlation with traditional hypergeometric enrichment scores (not shown). However, although hypergeometric enrichment is used on a predefined list of genes, PF-values are calculated by considering the whole genomic distribution and, therefore, can identify processes with consistent, albeit subtle, distribution of input values for constituent genes. Figure 3a shows a heatmap of PF-values for most significant processes for respective mutations in BRCA. In accordance with transcriptional footprint analyses, PIK3CA and AKT1 mutations have highly similar pathway footprints, whereas ERBB2 and EGFR have highly different pathway footprints that often were in opposite direction to each other or to PIK3CA/AKT1 footprints. For example, although breast cancers with ERBB2 amplifications have an extensive upregulation of the fatty acid and cholesterol biosynthesis machinery, PIK3CA or AKT1 mutations were mainly associated with fatty acid breakdown through b-oxidation in the peroxisome and mitochondria (Figures 3b and c) . Therefore, although ERBB2-amplified tumors mainly switch on anabolic lipid metabolism, consistent with their high mTOR activity 15 (see Figure 2b ), PIK3CA and AKT1 mutant tumors mainly engage in oxidative lipid catabolism. On the hand, EGFR-amplified breast cancers did not have specific activations of any of these pathways, but were mainly characterized by an extensive and selective upregulation of the innate immunity pathways, particularly the tumor necrosis factor, cellular extravasation and TLR pathways (Figures 2a-c ). These observations demonstrate the heterogeneity of pathway activations impacted by different EGFR pathway mutations in breast cancer.
Heterogeneity of pathway footprints among EGFR-driven human cancers Next, we wanted to conduct a comparative analysis of pathway footprints associated with activating mutations or amplifications of EGFR or ERBB2 in BRCA, GBM, LGG and LUAD. As expected from the transcriptional footprint analyses, EGFR amplifications in GBM and LGG have a high similarity of pathway footprints that is not shared by any other tissue pair (Figure 4a ). As GBM and LGG are both brain tumors, this strengthens the conclusion that oncogenic functional footprints in cancers are highly tissue specific. However, we have observed a common effect among EGFR-related pathway footprints (see below).
Interestingly, both GBM and LGG pathway footprints are dominated by processes involved in the major histocompatibility complex (MHC) class I antigen presentation pathway. The MHC class I antigen presentation pathway is a ubiquitous pathway for the presentation of intracellular antigens on MHC class I receptors on the cell surface to CD8 þ T cells. This is an important innate immunity mechanism whereby cytotoxic T cells recognize foreign antigens in virus-infected and transformed cells. 16, 17 It is striking that genes functioning at almost every step of this pathway, starting with the proteasomal degradation, endoplasmic reticulum calnexin/calreticulin system for recognition and loading of peptides, ATP-dependent peptide transporting machinery and endosomal/vacuolar delivery 17 are also overexpressed along with MHC class I complex proteins in GBM and LGG (see Figures 4a and  b) . Although the connection between EGFR amplification and innate immunity has not been reported in the literature, a role for MHC class I antigens in immune evasion in GBM have been proposed, 18 possibly suggesting a similar functional role for this pathway in EGFR þ GBM and LGG.
Strikingly, although MHC class I pathway seems to be unique to EGFR-amplifying GBMs and LGGs, LUADs with EGFR mutations, but not amplifications, seem to overexpress components of MHC class II machinery (see Figure 4a) . In contrast to MHC class I, MHC class II is mainly involved in the presentation of extracellular antigens. Therefore, instead of the proteasome-endoplasmic reticulum-Golgi route in MHC class I presentation, MHC class II involves phagocytosis of extracellular antigens, digestion in the lysosome, packaging into MHC class II complexes and recycling back to the cell surface. 17 Accordingly, in addition to MHC class II complex genes, EGFR-driven lung cancers also have significant overexpression of the lysosomal degradation machinery (see Figures 4a and b) . Consistent with an increased innate immunity signaling, LUADs, GBMs and LGGs driven by EGFR seem to have upregulated interferon signaling. Thus, it appears that a common innate immunity signaling machinery that triggers the production of genes involved in MHC class I and II presentation pathways are activated in brain and lung cancers driven by EGFR (Figure 4b) .
Although ERBB2-amplifying breast cancers do not display any inflammatory response signature, EGFR-amplifying breast cancers have a significant upregulation of the tumor necrosis factor, TLR and interleukin pathway signaling, possibly converging on nuclear factor-kB, interleukin-receptor activated kinase 1-2 and receptor-interacting serine/threonine kinase pathways (Figures 4a, c and d) . Therefore, it is likely that EGFR-driven human cancers are commonly characterized by an innate immunity signature; however, the pathways associated with innate immunity are tissue specific. At least in GBMs, specific activation of these pathways was associated with significant hypomethylation of respective genes, as demonstrated in Figure 4e for a representative gene SOCS2 (suppressor of cytokine signaling 2), a major target of cytokine signaling.
Effects of the tumor microenvironment on the functional footprints The presence of non-tumor cells in a tissue sample can be a significant confounding factor, and our findings of a strong inflammatory phenotype in EGFR-driven cancers may suggest an indirect effect of infiltrating immune cells or of tissue necrosis. TCGA provides information on tumor cell percentage, lymphocyte and monocyte infiltration, as well as necrosis percentages for the analyzed tumor specimens, which are among the primary factors that could elicit an inflammatory phenotype. We first tested whether EGFR amplification (in BRCA and GBM) or mutations (in LUAD) correlate with these factors. It should be noted that in the case of LGG, the percentage of tumor necrosis was 0 (zero) for all but one measured sample (consistent with their low-grade status), whereas the other parameters were mostly not indicated, suggesting that at least tumor necrosis was not responsible for the inflammatory phenotype in these tumors. Tumor necrosis and lymphocyte infiltration did not significantly correlate with EGFR amplification status in BRCA or GBM, but EGFR mutations in LUAD significantly correlated with tumor necrosis (Figure 5a ). This suggests that at least for LUAD, the inflammatory phenotype associated with EGFR mutations may be due to tumor necrosis. To test for the role of tumor necrosis and lymphocyte infiltration (monocyte infiltration was not adequately annotated for tumor samples) in the expression of respective inflammatory pathways, we included these parameters in our MLR model. As expected, tumor necrosis was a significant independent predictor of increased tumor necrosis factor and TLR2 pathway genes in BRCA, and lymphocyte infiltration was a significant independent predictor of MHC class II complex expression in LUAD (Figure 5b) . However, EGFR amplifications in BRCA and GBM, and EGFR mutations in LUAD were still strongly correlated with the expression of respective inflammatory pathways after controlling for tumor necrosis and lymphocyte infiltration (Figure 5b ). This indicates that the inflammatory phenotypes of EGFR-driven human cancers are likely to be tumor cell specific, rather than an artifact of immune cell infiltration.
Variable levels of genome instability among EGFR-driven human cancers Despite significant heterogeneity of pathway footprints, there is a consistently high expression of genes involved in positive regulation of cyclin-dependent kinase activity, indicating a common proliferative phenotype of EGFR-driven human cancers (Figure 4a) . However, interestingly, PLK1 signaling, DNA replication checkpoint and nucleotide-excision repair machinery seem to be highly expressed only in LGG (Figures 6a and b) , but expressed at a low level in LUAD (Figure 6a ). We asked whether such a pattern of expression of DNA repair machinery reflects cellular response to a high mutational load. To answer this question, we ranked patient samples in each data set by the number of their non-synonymous mutations and assigned them a normalized 'relative mutational load' score from 0 to 1, such that 0 indicates the patient sample with the least number of nonsynonymous mutations for a given tissue and 1 indicates the patient sample with the highest number of non-synonymous mutations. We have found that, consistent with the expression of DNA repair and checkpoint machinery, although EGFR-driven LGG and EGFR/ERBB2-driven BRCA are associated with a significantly high mutational load, EGFR-driven LUADs have a lower mutational load relative to other LUADs (Figure 6c) . Therefore, in addition to pathway footprint heterogeneity, EGFR-driven cancers of different origins also display different levels of genomic instability, which may explain some of the observed pathway heterogeneity.
Discrepancy of functional footprints between cancer cell lines and tissues Cancer cell lines are extensively used to study oncogenic mechanisms and their targetable vulnerabilities. With the availability of extensive genomic data for a large panel of cancer cell lines, it is now possible to conduct comparative analyses of functional architectures in cancer cell lines and tissues. 19, 20 Cancer cell lines of at least some tissue origins have been shown to closely resemble respective primary cancers in situ in terms of genomic make-up and overall transcriptional profiles. 21 However, to our knowledge, no analyses have been done to test for consistency of genotype-specific functional architectures in cell lines. As our analyses reveal a disconnect between EGFR pathway activation signatures and current knowledge, which is mainly based on in vitro studies, we decided to conduct a comparative analysis of EGFR pathway functional footprints in cancer cell lines. Using the genomic data sets from the 'Genomics of drug sensitivity' project 19 (the only one that has somatic mutation and copy number change data for select oncogenes/tumor suppressors and microarray gene expression data for cell lines), we calculated transcriptional footprints of cancer cell lines of the breast, colon, lung and malignant melanoma for mutations that had sufficient number of samples. Correlation profiles of oncogenic transcriptional footprints among cancer cell lines were generally consistent with those of tissues, with strongest correlations being observed between KRAS and BRAF footprints in the colon, and NRAS and BRAF footprints in melanoma (Figure 7a ). In accordance with the clinical data sets, intertissue correlations for most footprints were generally weaker, although the BRAF footprint in melanoma cells showed a strong similarity to the BRAF and KRAS footprints in the colon, but not the lung cancer cell lines.
Next, we sought to test for consistency of EGFR pathway footprints between clinical and cell line data sets. To allow for higher-confidence correlations, we calculated two independent transcriptional footprints for each mutation in each cancer type using two independent sets of patient samples in the respective clinical data sets in TCGA. Thus, our source data sets consisted of two independent sets of clinical and one set of cell line data sets. A correlation profile of oncogenic footprints in clinical and cell line samples reveals a high consistency between clinical footprints, which attests to their reproducibility in independent data sets ( Figure 7b ). However, oncogenic footprints in cell lines generally correlated weakly, albeit still generally statistically significantly, with their corresponding footprints in clinical data sets. For example, in breast cancer data sets, transcriptional footprints of ERBB2 amplification or PIK3CA mutations are highly similar in the two clinical data sets, but they are less similar to the respective footprints in cell lines (Figure 7b) . A particularly interesting profile emerges in the colon cancer data sets, where although the transcriptional footprints of KRAS and BRAF mutations seem to have diverged in cell lines, they have retained their similarities to each other. Overall, the high consistency of results between independent clinical data sets suggests that our calculated transcriptional footprints likely reflect true functional impacts of the respective mutational events in situ. However, our results also reveal a high level of divergence of cellular functional make-up during in vitro propagation of cell lines, which could explain the high level of disconnect between our findings and the current knowledge of EGFR pathway mechanisms in tumorigenesis.
DISCUSSION
Most of our current understanding of the tumorigenic mechanisms stems from in vitro studies on tissue culture and in vivo studies on mouse models of cancer. Although the signaling pathways operating downstream of receptor tyrosine kinases and the mechanistic details of many downstream interactions are currently well characterized, we do not know how relevant these mechanisms are in the clinical setting. As most of the current therapeutic efforts rely on these mechanisms, [3] [4] [5] it is vital that we dissect clinically relevant mechanisms from those induced by experimental artifacts. Although past studies have reported on global classification of tumor types based on their transcriptional profiles, 22 to our knowledge, the current study is the first comprehensive analysis of the TCGA data sets to delineate mutation-specific transcriptional, signaling and pathway profiles across clinical human cancer specimens. Despite several correlations consistent with the current view, our analyses reveal significant discrepancy of in vivo functional profiles of tumors with the currently accepted model of EGFR pathway-driven tumorigenesis.
MLR to identify functional footprints Correlating alterations at the DNA level to changes at the mRNA and phenotypic levels to infer causal relationships have been done previously under different contexts. 23, 24 For example, Akavia et al. 24 used Bayesian approaches modified from Segal et al. 25 to identify driver pathways downstream of copy number alterations in melanoma. Our approach in this study makes use of MLR to score the individual impact of each EGFR pathway mutation on the expression of every gene (transcriptional footprint) or protein state (signaling footprint). Such an approach allows for derivation of unique scores (t-values), explaining the relative impact of a gene mutation or copy number gain on a functional trait, which can be integrated with a priori molecular networks to derive pathways of interest. In contrast to the approach of Akavia et al., 24 we do not predefine modules of coregulated genes, but rather elect to evaluate the whole distribution of t-values (a footprint). This approach may have advantages over modulebased approaches when expressions of genes in a pathway may not necessarily correlate. For example, we have found that VCP and SYVN1, central members of the endoplasmic reticulumassociated degradation pathway, are both significantly upregulated in ERBB2-amplifying breast cancers, although their expressions in ERBB2-amplifying breast cancers show a slight mutually exclusive pattern. NetWalk analysis of MLR results identifies this pathway as significantly upregulated in ERBB2 þ breast cancers, and we showed that this pathway has a requisite role in the survival of ERBB2 þ breast cancer cells (manuscript under consideration elsewhere). A module-based approach, such as that of Akavia et al., 24 would probably have missed this correlation owing to the lack of correlation of expressions among endoplasmic reticulum-associated degradation member genes.
Tissue and oncogene specificity of functional footprints Our findings suggest that the global transcriptional and signaling programs activated by driver mutations of the EGFR pathway can be both tissue and mutation specific. Even in the case of the same oncogene, EGFR, its activating mutations in LUADs can have markedly different functional footprints from those of EGFR amplifications at transcriptional, signaling and pathway levels. This finding may not be surprising, given that patients with EGFR mutations in non-small cell lung cancers respond differently to treatment with EGFR inhibitor gefitinib compared with those with EGFR copy number gains, 26, 27 implying different cellular functional roles of the two mechanisms of EGFR activations.
EGFR mutations or amplifications also have markedly different profiles across different tissues (Figures 1-4) . Although EGFR amplifications in GBM and LGGs, both brain cancers, had highly similar functional footprints, they were significantly different from EGFR mutations or amplifications in other cancers. Moreover, strikingly, EGFR activations were not generally associated with the activation of downstream Akt and MAPK pathways in cancers. This and other observations (for example, no correlation of BRAF mutation with MAPK activation) are in contrast to the currently, widely accepted mechanisms of signal transduction downstream of these oncogenes. 3, 5, 6 At least in the case of rare genotypes (for example, EGFR amplifications in breast cancer), some of the discrepancy could be credited to the low statistical power due to small sample sizes, which may prevent accurate measurement of functional footprints. Another possible explanation for this discrepancy is that our analyses are entirely based on analyses of tumor samples, with no normal control, for which no RPPA data are available in TCGA. Therefore, it is possible that although MAPK levels are consistently activated in the majority of tumor samples, our analysis interprets a less-pronounced activation of MAPK by one mutation (for example, EGFR amplification in GBM) as a lack of activation due to the higher overall baseline across all tumor samples. However, we argue that the panel of tumor samples in each data set, where no mutations in either of these tested EGFR pathway genes exist, could serve as an internal control for our purposes, at least in this case. Therefore, our conclusion that a given oncogenic activation does not significantly further contribute to the activation of MAPK or AKT pathways is valid in light of these data. Accordingly, MAPK levels in EGFR-mutated or -amplified lung cancers are not significantly higher than in patients that have no activating mutations/amplifications in EGFR, KRAS, BRAF or NF1 (Supplementary Figure 2) .
In addition, it is important to note that a bulk of studies on EGFR signaling pathways were conducted in in vitro conditions, often involving growth factor stimulations after prolonged cellular starvation, and therefore may be affected by tissue culture artifacts. Accordingly, we show that the oncogenic functional footprints show a high level of divergence in cell lines, despite retaining some similarities to the tumor tissue. Although largescale RPPA data for cancer cell lines to allow for a comparative analysis of signaling footprints have not been reported (to our knowledge), discrepancies between tumor tissue and cell lines at the signaling level have been reported. For example, Hegi et al. 12 reported that although downstream pathway activations in EGFRamplifying GBM cell lines in vitro was EGFR dependent, this dependency was not present in GBM patient tumors with EGFR amplifications. Such divergence of the functional make-up of tumor cells in the culture is not unexpected, as the tumor stroma may have an important role in the shaping of tumor molecular architecture in situ. Therefore, in vivo roles of EGFR pathway mutations are complex, are likely confounded by feedback and alternative pathway activations in an oncogene-and tissuespecific manner, and may be highly dissimilar to their counterparts in vitro. These results may invite skepticism about the suitability of cell line models of tumorigenesis and, more importantly, about the feasibility of targeting common nodes (for example, Akt, mTOR, MEK and MAPK) downstream different mutations in cancers, which is currently a major trend in cancertargeted therapeutics.
Despite the significant heterogeneity of functional footprints, EGFR-driven brain, lung and breast cancers showed a common activation of inflammatory response pathways, although the individual pathways differed in a tissue-specific manner. For example, EGFR-driven GBM and LGG were characterized by activation of interferon-MHC class I antigen presentation pathway, whereas EGFR-driven LUAD was characterized by interferon-MHC class II antigen presentation pathway. EGFR-amplifying breast cancers, on the other hand, had a significant activation of TLR and cytokine receptor pathways converging on nuclear factor-kB and interleukin-receptor activated kinase signaling. This finding of a common denominator in EGFR-driven cancers may have some therapeutic implications, especially given that EGFR-targeting drugs have not yet demonstrated significant efficacy in EGFRdriven cancers of tissues other than the lung.
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MATERIALS AND METHODS
Functional footprint
A functional footprint is a vector of individual impact scores of a mutation on the expression of each mRNA (transcriptional footprint) or protein (signaling footprint). To score individual impacts of mutations m k , k ¼ 1yl, on the expression of a gene i, x i , we construct a linear model of the form
where b ik represents the regression coefficient of mutation k for the expression of gene i, and E i is assumed to be independent normally distributed error terms. The b i values reflect the effects of mutations on the expression of a gene i (because the other way around is unlikely). For example, a highly positive b ik value would indicate that the mutation k positively contributes to x i ; for example, ERBB2 amplification leads to high ERBB2 mRNA expression; whereas a highly negative b ik would indicate a negative impact of the mutation on x i . Note that the b ik values indicate the magnitude of impact, but not the significance of the impact, due to the error associated with b ik . Therefore, for our analyses, we use the significance scores for b, or t-scores:
where sðb ik Þ represents the s.e. associated with b ik . The t-values directly reflect the significance of the impact of each mutation (for example, t41.96 indicates a positive impact with a P-value of o0.05).
We construct MLR with statistical interactions between pairs of mutations as
where b ijk represents the regression coefficient for the impact of interaction between mutations j and k on the expression of gene i.
Correlations of footprints
For correlations of the transcriptional footprints in Figures 1c and 7 , we did all pairwise correlations of the corresponding t-values. However, for each pairwise correlation, we only considered t-values that had an absolute value 42, which corresponds to a P-value of o0.05, in either of the two samples. The degrees of freedom for any of the pairwise correlations in such a manner were always 4500.
Data sets
Copy number (SNP6 platform), gene expression (RNAseq, Agilent), RPPA, methylomics and somatic mutations data sets (MAF files, level 2) were obtained from the TCGA (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp). The gene expression and mutation/amplification data for cancer cell lines were obtained from The Genomics of Drug Sensitivity project web site (http://www.cancerrxgene.org/). For analyses in Figure 7 , patient samples in each of the respective cancer types (BRCA, COAD, LUAD and SKCM) were randomly divided into two sample sets to obtain two independent transcriptional footprints for each mutational event in each cancer type.
Defining mutations
For activating mutations in oncogenes, following Vogelstein et al. 31 for criteria of an activating mutation, we only considered mutations that occurred at a relatively higher frequency (410%) in the same data set. This criterion for activating mutations did not significantly affect our results (not shown), as such mutations accounted for an overwhelming majority of oncogenic mutations in each data set (see Supplementary Text). To map genomic coordinates in MAF files to corresponding amino acid positions in proteins, we used ANNOVAR. 32 For inactivating mutations in tumor suppressor genes, we considered all mutations, regardless of their relative frequency. For amplifications, we considered a relative copy number value of 41 to indicate genomic amplification.
Scoring tumor lymphocyte infiltration and tumor necrosis
In TCGA, tumor lymphocyte infiltration and tumor necrosis are provided as percentage scores using at least two slides for each tumor sample. For our analyses, we chose the highest percentage of tumor lymphocyte infiltration or tumor necrosis in any of the slides for any given sample to serve as the tumor lymphocyte infiltration or tumor necrosis score.
Networks
A knowledgebase of functional interactions between gene products was assembled from online databases. Protein-protein interactions, including signaling relationships were obtained from HPRD, 33 MINT, 34 Reactome, 35 BIND, 36 BioGRID, 37 Nature Pathway Database (http://pid.nci.nih.gov/), Biocarta (http://www.biocarta.com/) and PathwayCommons; 38 transcription factor-gene target relationships were obtained from TRANSFAC, 39 ORegAnno, 40 ENCODE 41 and MSigDB. 42 Metabolic relationships between gene products were defined such that genes whose products catalyze consecutive reactions (that is, product of the reaction catalyzed by one is used as a reactant in the reaction catalyzed by the other gene product)
were assigned an interaction; metabolic reactions catalyzed by human gene products were obtained from HMDB, 43 BiGG 44 and KEGG. 45 To increase the coverage of our knowledgebase, we also assigned interactions between pairs of genes if they shared GeneRIFs assigned to them in Entrez Gene. 46 Overall, our knowledgebase consisted of 444 828 unique interactions among 18 722 genes, which is available from authors upon request.
Network analyses
To identify pathways/networks associated with transcriptional footprints (pathway footprints), we used NetWalk, a random-walk method for the scoring of functional pathways and network interactions. The individual impact scores (t-values) are used as weights (w ¼ e t : weights must be positive) in the transition probability matrix P in NetWalk:
where N i is the set of network neighbors of node i, and j 2 N i and p ij is the transition probability from node i to node j. We define visitation probabilities of nodes, p, in the random walk as the solution to the eigenvector equation:
where P ¼ fp ij g nn is the transition probability matrix, q is the restart probability for the random walk and 1 n is a unit vector of length n (total number of network nodes). The second term on the right-hand side is a matrix with rank one that (1) adds a restart probability to the random walker depending on the weights of nodes and (2) ensures that the equation converges to a unique p. Visitation probability of the network interaction between nodes i and j, m ij , is defined as
The vector l reflects the probabilities of the interactions at the end of the random walk process, and each m ij reflects the weights (t-values) of immediate nodes i and j, and the weights and connectivity of nodes in the local network neighborhood. To control for topological bias in the network, we also calculate m 0 ij , which is calculated by setting all w ¼ 1 (that is, all t ¼ 0). Final EF values are defined as the log-likelihood
As a pathway or a functional process is technically a set of interactions, we define probability of a pathway/functional process k, j k , as the cumulative probability of its constituent interactions:
Finally, a PF is the log-likelihood
NetWalk analyses were performed in NetWalker, a stand-alone software suite for network-based genomic data analyses. 14 
